公开(公告)号：US20250066506A1

公开(公告)日：2025-02-27

申请号：US18596319

申请日：2024-03-05

Applicant: GENMAB A/S

Inventor： Bart DE GOEIJ ,  Patrick VAN BERKEL ,  Kristin STRUMANE ,  Aran Frank LABRIJN ,  Joost J. NEIJSSEN ,  Joyce I. MEESTERS ,  Paul PARREN ,  Janine SCHUURMAN

IPC: C07K16/32 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61K47/68 ,  C07K16/10 ,  C07K16/28 ,  C07K16/46

Abstract: Bispecific antibodies which comprise antigen-binding regions binding to two different epitopes of human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods of preparing and using the antibodies are also disclosed.

公开(公告)号：US20250066487A1

公开(公告)日：2025-02-27

申请号：US18935875

申请日：2024-11-04

Applicant: ABL Bio Inc. ,  YUHAN CORPORATION

Inventor： Yeryoung YONG ,  Ui-Jung JUNG ,  Hyejin CHUNG ,  Kyeongsu PARK ,  Wonjun SON ,  Yangsoon LEE ,  Yeunju KIM ,  Eunsil SUNG ,  Youngkwang KIM ,  Youngdon PAK ,  Minji PARK ,  Jaehyun EOM ,  Hyoju CHOI ,  Moo Young SONG ,  Na Rae LEE ,  Young Bong PARK ,  Eun-Jung LEE ,  Eun-Jung LEE

IPC: C07K16/28 ,  A61K39/00 ,  A61K39/395

Abstract: Provided are an anti-4-1BB/anti-EGFR bispecific antibody, and a pharmaceutical composition and a method for treating and/or preventing a cancer using the same.

公开(公告)号：US20250066486A1

公开(公告)日：2025-02-27

申请号：US18825514

申请日：2024-09-05

Applicant: Orionis Biosciences Inc. ,  Orionis Biosciences BV

Inventor： Nikolai KLEY ,  Jan TAVERNIER ,  Lennart ZABEAU ,  Erik DEPLA

IPC: C07K16/28 ,  A61K38/17 ,  A61K38/21 ,  A61K39/395 ,  A61K39/40 ,  A61K39/42 ,  A61P25/00 ,  C07K14/47 ,  C07K16/00 ,  C07K16/18

Abstract: The present invention relates, in part, to agents that bind Clec9A and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the Clec9A binding agents and their use in the treatment of various diseases.

公开(公告)号：US20250066485A1

公开(公告)日：2025-02-27

申请号：US18944958

申请日：2024-11-12

Applicant: Morphic Therapeutic, Inc.

Inventor： Adrian S. Ray ,  Monica Montesinos ,  Hua Wang ,  Min Lu ,  Fu-Yang Lin

IPC: C07K16/28 ,  A61K31/4375 ,  A61K39/00 ,  A61P9/12

Abstract: The present invention provides methods and compositions for treating a lung or heart disease and/or a disease associated with increased expression or activity of integrin α5β1, comprising administering an integrin α5β1, inhibitor to a subject. Methods of treating or preventing pulmonary hypertension, pulmonary arterial hypertension (PAH), right ventricle failure, heart failure and fibrosis are also provided herein.

公开(公告)号：US20250066484A1

公开(公告)日：2025-02-27

申请号：US18949473

申请日：2024-11-15

Applicant: ImmunityBio, Inc.

Inventor： Hans G. Klingemann ,  Laurent H. Boissel

IPC: C07K16/28 ,  A61K39/00 ,  A61K45/06 ,  A61P35/00 ,  C07K14/54 ,  C07K14/55 ,  C07K14/705 ,  C07K14/725 ,  C07K14/735 ,  C12N5/0783

Abstract: Recombinant NK cells, and particularly recombinant NK-92 cells express an anti-B7-H4 chimeric antigen receptor (CAR) having an intracellular domain of FcεRIγ. Most notably, CAR constructs with an intracellular domain of FcεRIγ had a significantly extended duration of expression and cytotoxicity over time. The anti-B7-H4 CAR may be expressed from RNA and DNA, preferably from a tricistronic construct that further encodes CD16 and a cytokine to confer autocrine growth support. Advantageously, such constructs also enable high levels of transfection and expression of the recombinant proteins and provide a convenient selection marker to facilitate rapid production of recombinant NK/NK-92 cells.

公开(公告)号：US20250066482A1

公开(公告)日：2025-02-27

申请号：US18822338

申请日：2024-09-02

Applicant: Numab Therapeutics AG

Inventor： Tea GUNDE ,  Matthias BROCK ,  Christian HESS ,  Alexandre SIMONIN

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00

Abstract: The present invention relates to an isolated antibody which specifically binds human PDL1, and pharmaceutical compositions and methods of use thereof. The present invention further relates to a nucleic acid encoding said antibody, a vector comprising said nucleic acid, a host cell comprising said nucleic acid or said vector, and a method of producing said antibody.

公开(公告)号：US20250066474A1

公开(公告)日：2025-02-27

申请号：US18946033

申请日：2024-11-13

Applicant: Janssen Biotech, Inc.

Inventor： Kyle J. Bednar ,  Naresh Kumar ,  Sanjaya Singh ,  Danlin Yang ,  Rajkumar Ganesan

IPC: C07K16/28 ,  A61K39/00 ,  C07K16/46

Abstract: Provided herein are multispecific antibodies, that bind to CD79b and CD22, polynucleotides encoding them, vectors, host cells, methods of making and using them.

公开(公告)号：US20250066442A1

公开(公告)日：2025-02-27

申请号：US18933787

申请日：2024-10-31

Applicant: Altor BioScience LLC

Inventor： Hing C. Wong ,  Peter Rhode ,  Xiaoyun Zhu ,  Kai-Ping Han

IPC: C07K14/54 ,  A61K38/00 ,  A61K38/17 ,  A61K38/20 ,  C07K14/715 ,  C07K14/725 ,  C07K16/18 ,  C07K16/28 ,  C12N15/09 ,  C12N15/62 ,  C12P21/00 ,  G01N33/569

Abstract: The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making the proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention.

公开(公告)号：US20250064969A1

公开(公告)日：2025-02-27

申请号：US18940614

申请日：2024-11-07

Applicant: Suntec Medical, Inc.

Inventor： Chun-Ting Cheng ,  Yuan-Chung Tsai ,  Pauline Ying Lau

IPC: A61K47/69 ,  A61K9/107 ,  A61K47/54 ,  A61K47/60 ,  C07K16/28 ,  C07K16/32

Abstract: The present invention provides a method of treating an autoimmune disease including type 1 diabetes, inflammatory bowel disease, rheumatoid arthritis. multiple sclerosis, systemic lupus erythematosus, psoriasis, myasthenia Gravis, and Hashimoto's thyroiditis. The method comprises the step of administering to a subject in need thereof an effective amount of micelles having an outer shell comprising one or more polymer-flavonoid conjugates, optionally an inner shell comprising one or more flavonoid oligomer, and a drug encapsulated within the shells. The present invention also provides a method of treating an autoimmune disease by administering to a subject in need thereof an effective amount of one or more polymer-flavonoid conjugate or one or more flavonoid oligomers.

公开(公告)号：US20250064928A1

公开(公告)日：2025-02-27

申请号：US18639242

申请日：2024-04-18

Applicant: Janssen Biotech, Inc.

Inventor： Rachel KOBOS ,  Arnob BANERJEE ,  Jenna GOLDBERG ,  Katherine CHASTAIN

IPC: A61K39/395 ,  A61K39/00 ,  C07K16/28

Abstract: Embodiments of the present invention relate to methods of treating multiple myeloma in a subject in need thereof comprising administering to the subject a BCMAxCD3 bispecific antibody on a bi-weekly dosing schedule.